Dr Ashley Yocum speaks to ecancer about a study presented at ASH 2024 which is part of the Beat AML master clinical trial.

She highlights significant advancements in AML treatment, including the FDA's approval of venetoclax and azacitidine.

Patients are categorised by treatment type, showing varied overall survival rates, with non-intensive treatments averaging 6 months and venetoclax combinations reaching 13.2 months, while intensive treatments can achieve up to 40 months.

She believes that this is good indication to pursue these targeted treatments but also combine them with veneteclax and azacitidine.